Full-Time

Associate Director

Analytical Development & Quality Control

Entrada Therapeutics

Entrada Therapeutics

201-500 employees

Develops intracellular therapeutics using endosomal escape

Compensation Overview

$172k - $202k/yr

Boston, MA, USA

Hybrid

Remote role with preference for New England candidates able to work in the office one day weekly; monthly or quarterly travel to Boston is required.

PhD

Category
Biology & Biotech (1)
Required Skills
Quality Assurance (QA)

Get referred to Entrada Therapeutics

See people who can refer or advise you

Requirements
  • A Ph.D. in Organic Chemistry, Analytical Chemistry or a related discipline with a minimum of 6 years of late-stage and commercial Analytical Development and Quality Control experience in a biotechnology or pharmaceutical industry.
  • Extensive experience in regulatory filing, including Investigational New Drug, Investigational Medicinal Product Dossier, New Drug Application and Marketing Authorization Application submissions.
  • Strong knowledge and hands-on experience in regulatory requirements and guidelines from the International Council for Harmonisation, Food and Drug Administration, European Medicines Agency, United States Pharmacopeia and European Pharmacopoeia for quality control of oligonucleotide drug products in late-stage manufacturing.
  • Extensive knowledge of current Good Manufacturing Practice regulations and guidelines.
  • Experience contributing to product quality risk assessments to identify critical quality attributes and developing associated limits and specifications.
  • Ability to handle multiple high-priority tasks in parallel to meet organizational goals.
Responsibilities
  • Partner with internal cross-functional teams and external contract development and manufacturing organizations to provide Analytical Development and Quality Control support for late-stage activities, Process Performance Qualification campaigns and commercial manufacturing.
  • Develop and implement comprehensive Analytical Development and Quality Control strategies to support successful regulatory submissions and ensure commercial readiness.
  • Lead analytical method lifecycle management activities, including method transfer, validation, verification, comparability assessments and ongoing method performance monitoring.
  • Establish, scientifically justify and maintain analytical specifications and sampling plans throughout the product lifecycle.
  • Author, review and approve Analytical Development and Quality Control sections of regulatory submissions, including Investigational New Drug, Investigational Medicinal Product Dossier, New Drug Application, Marketing Authorization Application and post-approval supplements.
  • Provide Analytical Development and Quality Control expertise in support of health authority inspections and responses, ensuring documentation remains compliant with applicable global regulatory requirements.
  • Serve as the Analytical Development and Quality Control Subject Matter Expert during regulatory inspections, partner audits and quality system assessments, representing the function and ensuring inspection readiness.
  • Collaborate with Drug Substance and Drug Product Development and Manufacturing, Quality Assurance and Regulatory Affairs to support product development, technology transfer, commercialization and lifecycle management activities.
  • Establish and monitor key Analytical Development and Quality Control performance metrics and drive continuous improvement initiatives to enhance quality, regulatory compliance, operational efficiency and inspection preparedness.
Desired Qualifications
  • Strong knowledge of the Analytical Development and Quality Control requirements for late-stage and commercial oligonucleotide programs, especially phosphorodiamidate morpholino oligomer and peptide-phosphorodiamidate morpholino oligomer programs.
  • Strong knowledge and hands-on experience with regulatory requirements and guidelines for quality control of oligonucleotide drug products; phosphorodiamidate morpholino oligomer and peptide-phosphorodiamidate morpholino oligomer experience is a strong plus.

Entrada Therapeutics focuses on developing a new class of medicines to treat devastating diseases by delivering therapies inside cells. Its core technology, the Endosomal Escape Vehicle (EEV) platform, helps drugs escape from endosomes—cellular compartments that often trap or degrade treatments—so they can reach intracellular targets. The product pipeline centers on EEV-therapeutics, including candidates for Duchenne muscular dystrophy and other neuromuscular diseases, with ENTR-601-45 currently cleared by UK and EU regulators to begin clinical trials. What sets Entrada apart is its explicit emphasis on enabling intracellular delivery to access targets that were previously hard to treat, using a platform-agnostic delivery approach that can work with a range of therapeutics such as oligonucleotides. The company’s goal is to advance multiple EEV-therapeutics through clinical development to address rare and other hard-to-treat diseases and reach patients who need new treatment options.

Company Size

201-500

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2016

Get referred to Entrada Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 cash of $223.0 million funds operations into Q3 2027.
  • ELEVATE-45-201 Cohort 1 reads out in October 2026, creating a near-term catalyst.
  • Cohort 2 completed enrollment by August 2026, keeping multiple DMD readouts through Q1 2027.

What critics are saying

  • May 7, 2026 dystrophin rose only 2.36%, far below management’s double-digit expectations.
  • Avidity’s del-zota reported about 25% dystrophin in September 2025, outclassing Entrada’s benchmark.
  • Shareholder investigations filed May 17, 2026 amplify litigation risk if October data disappoints.

What makes Entrada Therapeutics unique

  • Entrada’s EEV platform targets intracellular delivery, not just DMD exon skipping.
  • May 7, 2026 ENTR-601-44 showed clean safety and statistically significant Time-to-Rise gains.
  • August 5, 2026 ENTR-601-45 advanced with DMC-backed dose escalation into a second program.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Associated Press
Aug 5th, 2026
Entrada Therapeutics reports Q2 2026 results with multiple DMD data readouts ahead

Entrada Therapeutics reported second quarter 2026 financial results, highlighting multiple upcoming clinical data readouts for its Duchenne muscular dystrophy programmes. The company expects to report ELEVATE-44-201 Cohort 1 open-label data by year-end 2026 and Cohort 2 data in Q1 2027. ELEVATE-45-201 Cohort 1 results are anticipated in October 2026. Cash, cash equivalents and marketable securities totalled $223.0 million as of 30 June 2026, down from $295.7 million at year-end 2025. The company expects these funds to support operations into Q3 2027. Net loss was $42.8 million for the quarter, compared to $43.1 million in the same period last year. Research and development expenses decreased to $35.4 million from $37.9 million year-on-year. The company also received UK regulatory authorisation to initiate a Phase 1/2 study of ENTR-601-50 in DMD patients amenable to exon 50 skipping.

Yahoo Finance
May 9th, 2026
Entrada Therapeutics' DMD trial shows early functional gains with clean safety profile

Entrada Therapeutics has reported initial results from its phase I/II ELEVATE-44-201 trial of ENTR-601-44 in ambulatory Duchenne muscular dystrophy patients. The study showed favourable safety and tolerability, with only mild to moderate adverse events and no serious safety issues. The trial enrolled eight participants aged 6 to 17, randomised 3-to-1 to receive the 6 mg/kg dose or placebo. Headache was the most common adverse event, with no renal safety concerns observed. The company reported early functional benefits, including statistically significant improvement in time-to-rise velocity versus placebo and positive trends in the 10-metre walk/run test. Whilst plasma exposure was lower than expected, Entrada anticipates higher exon skipping and dystrophin levels in later cohorts. The company expects several clinical milestones in 2026 across its DMD programme.

BioSpace
May 7th, 2026
Entrada crashes as Duchenne therapy comes in 'below expectations' in early study.

Entrada crashes as Duchenne therapy comes in 'below expectations' in early study. May 7, 2026 | Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset - a number that fell short of the company's prior guidance of a double-digit improvement. Entrada Therapeutics' investigational oligonucleotide increased dystrophin concentrations in a Phase 1/2 Duchenne muscular dystrophy but not to the degree that analysts or the company had been expecting. In the first dosing cohort of the Phase 1/2 ELEVATE-44-201 trial, ENTR-601-44 elicited a 2.36% increase in normalized dystrophin levels in muscle tissue six weeks after the last dose, according to a Thursday release - well short short of Entrada's prior guidance of a double-digit jump. Shares of the Boston-based biotech plummeted 50% before the opening bell on Thursday, hitting $8.01 apiece. Oppenheimer analysts called ENTR-601-44's performance "disappointing," noting that the result puts Entrada's dystrophin benefit lower than that of competitor Avidity Biosciences. In a Thursday morning investor note, the firm pointed to a September 2025 readout in which Avidity reported an approximately 25% increase in the protein for its own oligonucleotide therapy del-zota after one year of treatment. Importantly, no trials directly comparing the two have been conducted. William Blair had a similar assessment of Entrada's readout. "Measurements of dystrophin protein expression after ENTR-601-44 treatment, the main efficacy-based endpoint of focus for investors, showed a 2.36% increase from baseline, which missed our base case of 10% and also management's expectations," the analysts wrote in a Thursday note. On a more positive note, Oppenheimer homed in on ENTR-601-44's effects on time-to-rise (TTR) velocity, a robust measure of functional performance that, according to Entrada, is "used as an early prognostic factor for disease progression and loss of ambulation." Thursday's readout demonstrated an average TTR improvement of 0.08 in patients treated with Entrada's molecule. Oppenheimer called this magnitude of effect "clinically significant" and noted it is "larger than competitors, suggesting a potential clinical benefit." As for safety, Entrada touted a favorable overall profile for a 6-mg/kg dose of ENTR-601-44, with no serious side effects or adverse events triggering discontinuation. Oppenheimer found the "clean" safety profile encouraging, explaining that it "allows for dose escalation to 12-18mg/kg that can ultimately deliver a competitive profile." With Thursday's data, ELEVATE-44-201 will continue on to its second patient cohort, which will receive a 12-mg/kg dose of the drug. Dosing for this leg of the study has started, with data expected by year-end. ENTR-601-44 is an oligonucleotide therapy that binds to exon 44 in the dystrophin pre-mRNA, allowing the cell's splicing machinery to skip over the faulty exon, according to Entrada's website. This ultimately results in a shorter but functional dystrophin protein, helping maintain the function and integrity of muscle cells, which in patients with Duchenne muscular dystrophy (DMD) otherwise undergo progressive degeneration. Common complications of the disease include heart and lung problems, often leading to death. Sarepta Therapeutics' Amondys 45 and Vyondys 53 work similarly to ENTR-601-44, removing faulty exons from the final mRNA transcript and facilitating the expression of truncated but functional dystrophin. In November last year, the drugs failed their confirmatory Phase 3 study, unable to elicit significant motor improvements in patients over placebo. Sarepta has nevertheless submitted supplemental applications to the FDA for both drugs. Vyondys 53 was first approved in 2019 and Amondys 45 in 2021, both under the agency's accelerated pathway.

Associated Press
May 7th, 2026
Entrada Therapeutics reports Q1 2026 results with positive DMD trial data and $255M cash runway into Q3 2027

Entrada Therapeutics reported positive topline results from Cohort 1 of its ELEVATE-44-201 study in Duchenne muscular dystrophy, showing favourable safety and tolerability alongside early functional benefits. The study of ENTR-601-44 at 6 mg/kg demonstrated statistically significant improvement in Time to Rise velocity, with all adverse events classified as mild or moderate. The company reported cash, cash equivalents and marketable securities of $255 million as of 31 March 2026, providing runway into the third quarter of 2027. Entrada plans to report ELEVATE-45-201 Cohort 1 data in mid-2026 and ELEVATE-44-201 open-label period and Cohort 2 data by year-end 2026. Net loss for the first quarter was $39.7 million, compared to $17.3 million in the same period last year.

GlobeNewswire
May 6th, 2026
Entrada Therapeutics to announce topline results from Cohort 1 of participants with Duchenne muscular dystrophy treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 study on May 7, 2026.

Entrada Therapeutics to announce topline results from Cohort 1 of participants with Duchenne muscular dystrophy treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 study on May 7, 2026. BOSTON, May 06, 2026 (GLOBE NEWSWIRE) - Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company's website at www.entradatx.com. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and available for replay on the Entrada Therapeutics website for 90 days following the call. About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Investor Contact Karla MacDonald Chief Corporate Affairs Officer [email protected] Media Contact Megan Prock McGrath CTD Comms, LLC [email protected]